CoChat
Sign Up
Cited by 56

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease

Galvan, Laurie, André, Véronique M., Wang, Elizabeth A., Cepeda, Carlos, Levine, Michael S.·2012·Journal of Huntington's Disease
DOI 10.3233/jhd-2012-120009PMC PMC4116084
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jhd-2012-120009

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Reduced striatal DRD2 was consistently demonstrated in patients and murine models and its dysregulation is a sensitive measure of HD pathology.

    “In fact, reduced striatal DRD2 was consistently demonstrated in patients 45,46,47,48,49 and murine models 27,35,50,51 and its dysregulation is a sensitive measure of HD pathology 37 .”

    From SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington’s disease phenotypes (2021) · cites this paper as [45]

    The Abstract (page unavailable) says markers of indirect-pathway neurons are lost early in postmortem HD brains and genetic mouse models, and identifies those neurons as D2-receptor-expressing. But it does not identify reduced DRD2 itself as an early marker or establish that DRD2 dysregulation is a sensitive measure of HD pathology—the portion attributed to this source by citation 37. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 77

  1. [1]The Huntington’s Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes Cell 1993 72 6 971 83 8458085
  2. [2]Bird ED Chemical pathology of Huntington’s disease Annu Rev Pharmacol Toxicol 1980 20 533 51 6446256
  3. [3]Bonelli RM Hofmann P A systematic review of the treatment studies in Huntington’s disease since 1990 Expert Opin Pharmacother 2007 8 2 141 53 17257085
  4. [4]Heinsen H Rub U Gangnus D Jungkunz G Bauer M Ulmar G Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington’s disease Acta Neuropathol 1996 91 2 161 68 8787149
  5. [5]Kassubek J Gaus W Landwehrmeyer GB Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis Neurology 2004 62 3 523 4 author reply 4 14872054
  6. [6]Kremer HP Roos RA Dingjan G Marani E Bots GT Atrophy of the hypothalamic lateral tuberal nucleus in Huntington’s disease J Neuropathol Exp Neurol 1990 49 4 371 82 2141871
  7. [7]Petersen A Gil J Maat-Schieman ML Bjorkqvist M Tanila H Araujo IM Orexin loss in Huntington’s disease Hum Mol Genet 2005 14 1 39 47 15525658
  8. [8]Vonsattel JP Myers RH Stevens TJ Ferrante RJ Bird ED Richardson EP Jr Neuropathological classification of Huntington’s disease J Neuropathol Exp Neurol 1985 44 6 559 77 2932539
  9. [9]Vonsattel JP DiFiglia M Huntington disease J Neuropathol Exp Neurol 1998 57 5 369 84 9596408
  10. [11]Massouh M Wallman MJ Pourcher E Parent A The fate of the large striatal interneurons expressing calretinin in Huntington’s disease Neurosci Res 2008 62 4 216 24 18801393
  11. [12]Rosas HD Tuch DS Hevelone ND Zaleta AK Vangel M Hersch SM Diffusion tensor imaging in presymptomatic and early Huntington’s disease: Selective white matter pathology and its relationship to clinical measures Mov Disord 2006 21 9 1317 25 16755582
  12. [13]Kita H Kitai ST Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations Brain Res 1988 447 2 346 52 3390703
  13. [14]Wilson CJ Shepherd GW Basal Ganglia The synaptic organization of the brain Oxford Oxford University Press 1990 279 316
  14. [15]Bolam JP Hanley JJ Booth PA Bevan MD Synaptic organisation of the basal ganglia J Anat 2000 196 Pt 4 527 42 10923985 PMC1468095
  15. [16]Smith Y Raju DV Pare JF Sidibe M The thalamostriatal system: a highly specific network of the basal ganglia circuitry Trends Neurosci 2004 27 9 520 7 15331233
  16. [17]Kemp JM The site of termination of afferent fibres on the neurones of the caudate nucleus J Physiol 1970 210 1 17P 8P 5500777
  17. [19]Pisani A Bernardi G Ding J Surmeier DJ Re-emergence of striatal cholinergic interneurons in movement disorders Trends Neurosci 2007 30 10 545 53 17904652
  18. [20]Tepper JM Wilson CJ Koos T Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons Brain Res Rev 2008 58 2 272 81 18054796 PMC2562631
  19. [21]Cicchetti F Prensa L Wu Y Parent A Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease Brain Res Brain Res Rev 2000 34 1–2 80 101 11086188
  20. [22]Ferrante RJ Beal MF Kowall NW Richardson EP Jr Martin JB Sparing of acetylcholinesterase-containing striatal neurons in Huntington’s disease Brain Res 1987 411 1 162 6 2955849
  21. [23]Ferrante RJ Kowall NW Beal MF Richardson EP Jr Bird ED Martin JB Selective sparing of a class of striatal neurons in Huntington’s disease Science 1985 230 4725 561 3 2931802
  22. [24]Kawaguchi Y Wilson CJ Emson PC Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin J Neurosci 1990 10 10 3421 38 1698947 PMC6570194
  23. [25]Andre VM Cepeda C Cummings DM Jocoy EL Fisher YE William Yang X Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids Eur J Neurosci 2010 31 1 14 28 20092552
  24. [26]Shuen JA Chen M Gloss B Calakos N Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia J Neurosci 2008 28 11 2681 5 18337395 PMC6670676
  25. [27]Surmeier DJ Song WJ Yan Z Coordinated expression of dopamine receptors in neostriatal medium spiny neurons J Neurosci 1996 16 20 6579 91 8815934 PMC6578920
  26. [28]Gerfen CR Engber TM Mahan LC Susel Z Chase TN Monsma FJ Jr D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science 1990 250 4986 1429 32 2147780
  27. [29]Haber SN Nauta WJ Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry Neuroscience 1983 9 2 245 60 6192358
  28. [30]Vincent S Hokfelt T Christensson I Terenius L Immunohistochemical evidence for a dynorphin immunoreactive striatonigral pathway Eur J Pharmacol 1982 85 2 251 2 6129987
  29. [31]Albin RL Young AB Penney JB The functional anatomy of basal ganglia disorders Trends Neurosci 1989 12 10 366 75 2479133
  30. [32]Steiner H Gerfen CR Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons Neuroscience 1999 88 3 795 810 10363818
  31. [33]Albin RL Reiner A Anderson KD Dure LSt Handelin B Balfour R Preferential loss of striatoexternal pallidal projection neurons in presymptomatic Huntington’s disease Ann Neurol 1992 31 4 425 30 1375014
  32. [34]Menalled L Zanjani H MacKenzie L Koppel A Carpenter E Zeitlin S Decrease in striatal enkephalin mRNA in mouse models of Huntington’s disease Exp Neurol 2000 162 2 328 42 10739639
  33. [35]Reiner A Albin RL Anderson KD D’Amato CJ Penney JB Young AB Differential loss of striatal projection neurons in Huntington disease Proc Natl Acad Sci U S A 1988 85 15 5733 7 2456581 PMC281835
  34. [36]Richfield EK Maguire-Zeiss KA Vonkeman HE Voorn P Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington’s disease patients Ann Neurol 1995 38 6 852 61 8526457
  35. [37]Sapp E Ge P Aizawa H Bird E Penney J Young AB Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington’s disease using high resolution image analysis Neuroscience 1995 64 2 397 404 7535402
  36. [38]Deng YP Albin RL Penney JB Young AB Anderson KD Reiner A Differential loss of striatal projection systems in Huntington’s disease: A quantitative immunohistochemical study J Chem Neuroanat 2004 27 3 143 64 15183201
  37. [39]Albin RL Reiner A Anderson KD Penney JB Young AB Striatal and nigral neuron subpopulations in rigid Huntington’s disease: Implications for the functional anatomy of chorea and rigidity-akinesia Ann Neurol 1990 27 4 357 65 1972318
  38. [40]Hedreen JC Folstein SE Early loss of neostriatal striosome neurons in Huntington’s disease J Neuropathol Exp Neurol 1995 54 1 105 20 7815073
  39. [41]Spektor BS Miller DW Hollingsworth ZR Kaneko YA Solano SM Johnson JM Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington’s disease Brain Res Mol Brain Res 2002 102 1–2 118 28 12191502
  40. [42]Raymond LA André VM Cepeda C Gladding CM Milnerwood AJ Levine MS Pathophysiology of Huntington’s disease: Time-dependent alterations in synaptic and receptor function Neuroscience 2011 198 252 73 21907762 PMC3221774
  41. [43]Milnerwood AJ Gladding CM Pouladi MA Kaufman AM Hines RM Boyd JD Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice Neuron 2010 65 2 178 90 20152125
  42. [44]Okamoto S Pouladi MA Talantova M Yao D Xia P Ehrnhoefer DE Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin Nat Med 2009 15 12 1407 13 19915593 PMC2789858
  43. [45]Reiner A Jiao Y Del Mar N Laverghetta AV Lei WL Differential morphology of pyramidal tract-type and intratelencephalically projecting-type corticostriatal neurons and their intrastriatal terminals in rats J Comp Neurol 2003 457 4 420 40 12561080
  44. [46]Lei W Jiao Y Del Mar N Reiner A Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats J Neurosci 2004 24 38 8289 99 15385612 PMC6729697
  45. [47]Ballion B Mallet N Bezard E Lanciego JL Gonon F Intrate-lencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism Eur J Neurosci 2008 27 9 2313 21 18445222
  46. [48]Cepeda C Andre VM Yamazaki I Wu N Kleiman-Weiner M Levine MS Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons Eur J Neurosci 2008 27 3 671 82 18279319
  47. [49]Gertler TS Chan CS Surmeier DJ Dichotomous anatomical properties of adult striatal medium spiny neurons J Neurosci 2008 28 43 10814 24 18945889 PMC3235748
  48. [51]Gray M Shirasaki DI Cepeda C Andre VM Wilburn B Lu XH Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice J Neurosci 2008 28 24 6182 95 18550760 PMC2630800
  49. [52]Pouladi MA Graham RK Karasinska JM Xie Y Santos RD Petersen A Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin Brain 2009 132 Pt 4 919 32 19224899
  50. [53]Slow EJ van Raamsdonk J Rogers D Coleman SH Graham RK Deng Y Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease Hum Mol Genet 2003 12 13 1555 67 12812983
  51. [54]Van Raamsdonk JM Murphy Z Slow EJ Leavitt BR Hayden MR Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease Hum Mol Genet 2005 14 24 3823 35 16278236
  52. [55]Andre VM Cepeda C Fisher YE Huynh M Bardakjian N Singh S Differential electrophysiological changes in striatal output neurons in Huntington’s disease J Neurosci 2011 31 4 1170 82 21273402 PMC3071260
  53. [56]Andre VM Fisher YE Levine MS Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington’s disease Front Syst Neurosci 2011 5 46 21720523 PMC3118454
  54. [57]Joshi PR Wu NP Andre VM Cummings DM Cepeda C Joyce JA Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease J Neurosci 2009 29 8 2414 27 19244517 PMC2670193
  55. [58]Cepeda C Buchwald NA Levine MS Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated Proc Natl Acad Sci U S A 1993 90 20 9576 80 7692449 PMC47612
  56. [59]Cepeda C Colwell CS Itri JN Chandler SH Levine MS Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances J Neurophysiol 1998 79 1 82 94 9425179
  57. [60]Dumartin B Jaber M Gonon F Caron MG Giros B Bloch B Dopamine tone regulates D1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice Proc Natl Acad Sci U S A 2000 97 4 1879 84 10677550 PMC26530
  58. [61]Giros B Jaber M Jones SR Wightman RM Caron MG Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter Nature 1996 379 6566 606 12 8628395
  59. [62]Wu N Cepeda C Zhuang X Levine MS Altered corticostriatal neurotransmission and modulation in dopamine transporter knock-down mice J Neurophysiol 2007 98 1 423 32 17522168
  60. [63]Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial Neurology 2006 66 366 72 16476934
  61. [64]Pettibone DJ Pflueger AB Totaro JA Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine Eur J Pharmacol 1984 102 3–4 431 6 6149131
  62. [65]Mestre T Ferreira J Coelho MM Rosa M Sampaio C Therapeutic interventions for symptomatic treatment in Huntington’s disease Cochrane Database Syst Rev 2009 3 CD006456 19588393
  63. [66]Tang TS Chen X Liu J Bezprozvanny I Dopaminergic signaling and striatal neurodegeneration in Huntington’s disease J Neurosci 2007 27 30 7899 910 17652581 PMC3307545
  64. [67]Richfield EK Penney JB Young AB Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system Neuroscience 1989 30 3 767 77 2528080
  65. [68]Rice ME Cragg SJ Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway Brain Res Rev 2008 58 2 303 13 18433875 PMC2879278
  66. [69]Benn CL Slow EJ Farrell LA Graham R Deng Y Hayden MR Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease Neuroscience 2007 147 2 354 72 17544587 PMC1995552
  67. [70]Gittis AH Nelson AB Thwin MT Palop JJ Kreitzer AC Distinct roles of GABAergic interneurons in the regulation of striatal output pathways J Neurosci 2010 30 6 2223 34 20147549 PMC2836801
  68. [71]Boyden ES A history of optogenetics: the development of tools for controlling brain circuits with light F1000 Biol Rep 2011 3 11 21876722 PMC3155186
  69. [72]Yizhar O Fenno LE Davidson TJ Mogri M Deisseroth K Optogenetics in neural systems Neuron 2011 71 1 9 34 21745635
  70. [73]Gradinaru V Mogri M Thompson KR Henderson JM Deisseroth K Optical deconstruction of parkinsonian neural circuitry Science 2009 324 5925 354 9 19299587 PMC6744370
  71. [74]Kravitz AV Kreitzer AC Optogenetic manipulation of neural circuitry in vivo Curr Opin Neurobiol 2011 21 3 433 9 21420852 PMC3130851
  72. [77]Ellender TJ Huerta-Ocampo I Deisseroth K Capogna M Bolam JP Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine J Neurosci 2011 31 43 15340 51 22031880 PMC6703542
  73. [78]Lawrence AD Hodges JR Rosser AE Kershaw A ffrench-Constant C Rubinsztein DC Evidence for specific cognitive deficits in preclinical Huntington’s disease Brain 1998 121 Pt 7 1329 41 9679784
  74. [79]Paulsen JS Langbehn DR Stout JC Aylward E Ross CA Nance M Detection of Huntington’s disease decades before diagnosis: the Predict-HD study J Neurol Neurosurg Psychiatry 2008 79 8 874 80 18096682 PMC2569211
  75. [80]Goodchild RE Court JA Hobson I Piggott MA Perry RH Ince P Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington’s and Parkinson’s disease cases Eur J Neurosci 1999 11 2 449 56 10051746
  76. [81]Martinez-Mir MI Pollard H Moreau J Traiffort E Ruat M Schwartz JC Loss of striatal histamine H2 receptors in Huntington’s chorea but not in Parkinson’s disease: comparison with animal models Synapse 1993 15 3 209 20 7904088
  77. [82]van Wamelen DJ Shan L Aziz NA Anink JJ Bao AM Roos RA Functional increase of brain histaminergic signaling in Huntington’s disease Brain Pathol 2011 21 4 419 27 21106039 PMC8094306

Cited by

Sorted by citations

Metadata

Authors
Galvan, L., André, V. M., Wang, E. A., Cepeda, C., & Levine, M. S.
Affiliations
Intellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience and Human Behavior and the Brain Research Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
Venue
Journal of Huntington's Disease
Publisher
SAGE Publications
Published
2012
Volume
1
Issue
1
Pages
17-25
ISSN
1879-6397
DOI
10.3233/jhd-2012-120009
PMC
PMC4116084
Cited by
56
References
4
Licence
creativecommons.org/licenses/by-nc/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review